Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Y Diesendruck, I Benhar - Drug Resistance Updates, 2017 - Elsevier
Drug resistance of tumor cells to chemotherapy is limiting the therapeutic efficacy of most
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …
Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges.
Y Diesendruck, I Benhar - Drug Resistance Updates: Reviews and …, 2017 - europepmc.org
Drug resistance of tumor cells to chemotherapy is limiting the therapeutic efficacy of most
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …
Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Y Diesendruck, I Benhar - Drug Resistance Updates, 2017 - infona.pl
Drug resistance of tumor cells to chemotherapy is limiting the therapeutic efficacy of most
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …
Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges
Y Diesendruck, I Benhar - Drug resistance updates …, 2017 - pubmed.ncbi.nlm.nih.gov
Drug resistance of tumor cells to chemotherapy is limiting the therapeutic efficacy of most
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …
anticancer drugs and represents a major obstacle in medical oncology. However, treatment …